Evidence map›Paper›PMID 41078930›Full record

ArticleArchives of medical science : AMS2025

Different antinuclear antibody subgroups of anti-melanoma differentiation-associated gene 5-positive dermatomyositis showed variability in clinical presentation: a multicenter retrospective cohort study.

Gang Wang, Dong Yan, Leixi Xue, Chenghua Weng, Lei Zhang, Lingxiao Xu, Fenghong Yuan, Ju Li, Min Wu, Zhanyun Da and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of medical science : AMS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Gang WangDepartment of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Dong YanDepartment of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Leixi XueDepartment of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Chenghua WengDepartment of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Lei ZhangDepartment of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Lingxiao XuDepartment of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Fenghong YuanDepartment of Rheumatology and Immunology, Wuxi People's Hospital, Wuxi, Jiangsu, China.
Ju LiDepartment of Rheumatology and Immunology, Huai'an First People's Hospital, Huai'an, Jiangsu, China.
Min WuDepartment of Rheumatology and Immunology, The First People's Hospital of Changzhou, Changzhou, Jiangsu, China.
Zhanyun DaDepartment of Rheumatology and Immunology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Hua WeiDepartment of Rheumatology and Immunology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China.
Lei ZhouDepartment of Rheumatology and Immunology, Changzhou No. 2 People's Hospital, Changzhou, Jiangsu, China.
Songlou YinDepartment of Rheumatology and Immunology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Jian WuDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Yan LuDepartment of Rheumatology and Immunology, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu, China.
Dinglei SuDepartment of Rheumatology and Immunology, Nanjing First Hospital, Nanjing, Jiangsu, China.
Lin LiuDepartment of Rheumatology and Immunology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China.
Longxin MaDepartment of Rheumatology and Immunology, Yancheng No. 1 People's Hospital, Yancheng, Jiangsu, China.
Xiaoyan XuDepartment of Rheumatology and Immunology, Zhongda Hospital Southeast University, Nanjing, Jiangsu, China.
Huijie LiuDepartment of Rheumatology and Immunology, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China.
Tianli RenDepartment of Rheumatology and Immunology, Wuxi No. 2 People's Hospital, Wuxi, Jiangsu, China.
Yinshan ZangDepartment of Rheumatology and Immunology, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, Jiangsu, China.
Zhichun LiuDepartment of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Antinuclear antibodies (ANA) are frequently positive in patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis (anti-MDA5+ DM). This study aimed to investigate the association between ANA and clinical characteristics as well as prognosis in a cohort of patients with anti-MDA5+ DM. Material and methods: We conducted a systematic retrospective study of medical records from a Nanjing Medical University cohort of patients with myositis-associated interstitial lung disease (ILD). Various parameters were compared and analyzed between the ANA-positive group and the ANA-negative group. Results: A total of 246 patients with anti-MDA5+ DM were enrolled in this study, with 28.5% males and 71.5% females. The median age was 53.0 years, the median disease duration was 2 months, and the median follow-up period was 12.0 months. The ANA positivity rate at baseline was 52.4% in anti-MDA5+ DM patients. The ANA-positive group showed significantly higher positivity rates of anti-Ro52 antibodies (72.9% vs. 54.7%, Conclusions: ANA is frequently found in patients with anti-MDA5+ DM. High titers of anti-MDA5 antibodies are associated with mortality and RPILD.

Indexed as

anti-MDA5+ dermatomyositisantinuclear antibodydermatomyositisrapidly progressive interstitial lung diseasesubgroup analysis

Identifiers

PMID41078930
PMCPMC12509802

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.